Recent Updates
Recently added Catalysts
CUVL Positive Sentiment

SCENESSE® approved for EPP in Canada

Monday, July 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: CLINUVEL's SCENESSE® has been approved for the treatment of Erythropoietic Protoporphyria (EPP) in Canada. This approval signifies an important milestone for the company and enhances the therapeutic options available to patients suffering from this rare condition. The move reflects CLINUVEL's commitment to expanding its reach in the pharmaceutical market.

Market Sentiment Analysis

POSITIVE FACTORS

  • SCENESSE® has received approval for EPP in Canada.
  • This approval expands treatment options for patients.
  • CLINUVEL continues to advance its product offerings.

Full Press Release Details

• About About CLINUVEL People Corporate Governance Photomedicine Foundation Annual Reports
• Pharmaceuticals Pharmaceutical Development The Science Disease Entities Products
• PhotoCosmetics About PhotoCosmetics Polychromatic Photoprotection DNA Repair Melanogenesis
• Investors Investors Information ASX Announcements SEC Filings Analyst Coverage Media Coverage Company Snapshot Financial Summary Shareholder Information Investor Enquiry
• News
• Contact
• Store
• About CLINUVEL
• People
• Corporate Governance
• Photomedicine Foundation
• Annual Reports
• Pharmaceutical Development
• The Science
• Disease Entities
• Products
• About PhotoCosmetics
• Polychromatic Photoprotection
• DNA Repair
• Melanogenesis
• Investors Information
• ASX Announcements
• SEC Filings
• Analyst Coverage
• Media Coverage
• Company Snapshot
• Financial Summary
• Shareholder Information
• Investor Enquiry

Frequently Asked Questions

What is SCENESSE® approved for?

SCENESSE® is approved for the treatment of Erythropoietic Protoporphyria (EPP).

In which country was SCENESSE® approved?

SCENESSE® was approved in Canada.

What does this approval mean for patients?

The approval expands treatment options for patients with EPP.

Which company developed SCENESSE®?

SCENESSE® was developed by CLINUVEL.

ShareAdd on Google
Tags: CUVL Viatris Investor Conferences Healthcare SCENESSE EPP CLINUVEL Canada pharmaceuticals
Last updated: Jul 13, 2026

Biotech snapshot

Lead asset
Afamelanotide and NB-UVB LightPhase 3
Vitiligo →